LON:STX - Shield Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 61.28 -1.23 (-1.97 %)
(As of 03/22/2019 12:44 PM ET)
Previous CloseGBX 62.50
Today's RangeGBX 60.50 - GBX 62.20
52-Week RangeGBX 14 - GBX 73
Volume30,695 shs
Average Volume48,665 shs
Market Capitalization£71.34 million
P/E Ratio-3.95
Dividend YieldN/A
BetaN/A
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its Phase IIb pivotal clinical trial for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also develops PT30 and PT40 intravenous iron formulations. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Receive STX News and Ratings via Email

Sign-up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-191-5118500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£990,000.00
Cash FlowGBX 2.76 per share
Book ValueGBX 28.80 per share

Profitability

Miscellaneous

Employees20
Market Cap£71.34 million
Next Earnings DateN/A
OptionableOptionable

Shield Therapeutics (LON:STX) Frequently Asked Questions

What is Shield Therapeutics' stock symbol?

Shield Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "STX."

What price target have analysts set for STX?

2 brokerages have issued 1 year price targets for Shield Therapeutics' shares. Their predictions range from GBX 88 to GBX 116. On average, they expect Shield Therapeutics' stock price to reach GBX 102 in the next year. This suggests a possible upside of 66.5% from the stock's current price. View Analyst Price Targets for Shield Therapeutics.

What is the consensus analysts' recommendation for Shield Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Shield Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Shield Therapeutics.

Has Shield Therapeutics been receiving favorable news coverage?

Headlines about STX stock have been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Shield Therapeutics earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.

Who are some of Shield Therapeutics' key competitors?

What other stocks do shareholders of Shield Therapeutics own?

Who are Shield Therapeutics' key executives?

Shield Therapeutics' management team includes the folowing people:
  • Mr. Carl Sterritt, Co-Founder, CEO & Director (Age 51)
  • Mr. Timothy William Watts, Chief Financial Officer (Age 61)
  • Fleur Wood, Director of Investor Relations
  • Ms. Lucy Bailey, Gen. Counsel & Company Sec.
  • Ms. Suzanne Wood, Group HR Director

How do I buy shares of Shield Therapeutics?

Shares of STX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shield Therapeutics' stock price today?

One share of STX stock can currently be purchased for approximately GBX 61.28.

How big of a company is Shield Therapeutics?

Shield Therapeutics has a market capitalization of £71.34 million and generates £990,000.00 in revenue each year. Shield Therapeutics employs 20 workers across the globe.

What is Shield Therapeutics' official website?

The official website for Shield Therapeutics is http://www.shieldtherapeutics.com/.

How can I contact Shield Therapeutics?

Shield Therapeutics' mailing address is 3rd Fl Baltic Business Quarters, Abbott's Hill, GATESHEAD, NE8 3D, United Kingdom. The company can be reached via phone at +44-191-5118500.


MarketBeat Community Rating for Shield Therapeutics (LON STX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  160 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  275
MarketBeat's community ratings are surveys of what our community members think about Shield Therapeutics and other stocks. Vote "Outperform" if you believe STX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel